Sangamo Therapeutics (NASDAQ:SGMO) Rating Lowered to Strong Sell at Wall Street Zen

Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Saturday.

Several other research firms have also commented on SGMO. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sangamo Therapeutics in a research report on Wednesday, October 8th. Barclays reiterated an “equal weight” rating and set a $1.00 price objective (down previously from $5.00) on shares of Sangamo Therapeutics in a research report on Friday, November 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Thursday, September 4th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $3.83.

Sangamo Therapeutics Trading Down 1.0%

SGMO opened at $0.44 on Friday. The company has a market cap of $149.64 million, a P/E ratio of -1.53 and a beta of 1.25. Sangamo Therapeutics has a 12 month low of $0.41 and a 12 month high of $2.84. The business’s 50-day moving average price is $0.59 and its 200-day moving average price is $0.55.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.08). The business had revenue of $0.58 million for the quarter, compared to analysts’ expectations of $34.40 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. Equities research analysts forecast that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of large investors have recently bought and sold shares of the business. Golden State Equity Partners raised its position in shares of Sangamo Therapeutics by 5.4% during the 2nd quarter. Golden State Equity Partners now owns 391,943 shares of the biopharmaceutical company’s stock valued at $212,000 after buying an additional 20,000 shares during the period. World Investment Advisors raised its holdings in Sangamo Therapeutics by 88.5% in the 3rd quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 20,000 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in Sangamo Therapeutics by 30.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 90,550 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 21,300 shares during the last quarter. Wealth Management Associates Inc. lifted its holdings in shares of Sangamo Therapeutics by 9.1% in the 3rd quarter. Wealth Management Associates Inc. now owns 335,800 shares of the biopharmaceutical company’s stock worth $226,000 after acquiring an additional 28,000 shares during the last quarter. Finally, Meritage Portfolio Management boosted its position in shares of Sangamo Therapeutics by 37.3% during the 2nd quarter. Meritage Portfolio Management now owns 127,000 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 34,500 shares during the period. Institutional investors and hedge funds own 56.92% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.